Freshly Funded Symic Bio Plays In The Matrix
Emerging Company Profile: Symic Bio recently raised $30m in a Series B financing. CEO Ken Horne talks about the firm's therapeutic focus on the body's extracellular matrix as a therapeutic target, and its two lead programs in peripheral vein graft failure prevention and knee osteoarthritis.
You may also be interested in...
Private Company Edition: With academic muscle, Google cash and nanoparticles, and various CRISPR licenses, Verve will develop gene-editing therapies for coronary heart disease prevention. Also, Vividion raises an $82m series B and two Belgian companies bring in $77.8m in VC cash.
Bicycle closes a $52m Series B to test its bicyclic peptides in humans, while Decipera, Harpoon and TP Therapeutics also top a $263m list of recent venture capital deals. In public company financings, Alnylam, Aerie and others price offerings to raise cash while their stocks are on the rise.
Infographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics.